Securing the exemption from CVA charges in the new bank capital rules within the EU was a crucial element of the EACT's campaign to ensure that OTC derivatives continued to be available to corporates for risk management and that the pricing remained competitive. Policy in the United States towards the CVA exemption has been and remains a concern to the EACT. In March, the EACT Chairman wrote to Mr Daniel Pinto, Co-CEO Corporate & Investment at JP Morgan, to seek clarity on the position of the bank with respect to the EU CVA exemption and to ask what action has been undertaken by the bank in the last six months. In his response, Mr. Pinto stated that JP Morgan has not called for a repeal of the CVA exemption for corporate end users, yet also expressed concern that the approach by the regulators was not globally consistent and, as such, creates competitive inequalities.
The EACT Board would like to personally thank all our delegates and sponsors in attendance at last week's EACT Summit.
View MoreEACT representatives were delighted to announce the three winners of this year's EACT Award during a ceremony at the recent Summit in Brussels.
View MoreEACT is proud to partner with RedCompass Labs to sponsor the 2024 European Instant Payments Survey.
View MoreJoin us at the ACT Annual Conference at ACC Liverpool, UK, on 21-22 May 2024. A limited number of free places are available for EACT members.
View MoreThe European Associations of Corporate Treasurers (EACT) is pleased to invite its members to submit nominations for the 5th EACT Award in 2024.
View More